What's Hot

View all perspectives
      RT @Janetbirdope: #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if

      Janet Pope Janetbirdope

      1 year 4 months ago
      #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 @RheumNow #EULAR2023 @eular_org https://t.co/XWphyEO2JJ
      RT @AurelieRheumo: Natural sequence of events happening in a subclinically inflamed joint, serial MRI study

      When progre

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      Natural sequence of events happening in a subclinically inflamed joint, serial MRI study When progressing to clinical RA First osteitis then synovitis & tenosynovitis 🦴➡️✋ During resolution tenosynovitis reduces first then synovitis & osteitis @RheumNow #EULAR23 OP0261 https://t.co/ic94htYv6T
      RT @Yuz6Yusof: #EULAR2023 #POS1133 Consistent with clinical response in Phase 2 RCT, therapy with Updacitinib alone and

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #POS1133 Consistent with clinical response in Phase 2 RCT, therapy with Updacitinib alone and ABV599-HD (Elsubrutinib + Upadacitinib) modulated IFN-I signalling pathways (IFN gene expression & proteomics). Assuring therapeutic evidence @RheumNowNews https://t.co/27mtCNg76X
      RT @bella_mehta: Long term data on Canakinumab - IL-1B antibody in #AOSD @EULAR2023 25 pts with persistent disease activ

      Bella Mehta bella_mehta

      1 year 4 months ago
      Long term data on Canakinumab - IL-1B antibody in #AOSD @EULAR2023 25 pts with persistent disease activity, f/u 12 mths, remission in all but 2 pts. Improved parameters as below :- @rheumnow abst#OP0257 https://t.co/7jKTp87FlX
      RT @Yuz6Yusof: #EULAR2023 #OP0226 DORIS remission in #SLE is a goal but may be slight tricky to achieve. Multicentre coh

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #OP0226 DORIS remission in #SLE is a goal but may be slight tricky to achieve. Multicentre cohort study showed attainment of LLDAS protected against subsequent Flare and Damage @RheumNow https://t.co/MIypIDW6aE
      RT @drdavidliew: For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs.

      @eu

      David Liew drdavidliew

      1 year 4 months ago
      For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs. @eular_org points to consider SLR: no clear risk, across b/tsDMARDs For too long these patients were unnecessarily asked to ride it out. No more please POS1069 #EULAR2023 @RheumNow https://t.co/7m4Yh0h7rd
      RT @drdavidliew: We know HCQ adherence is poor in both RA and SLE
      >50% in this BC 🇨🇦 cohort
      All despite being s

      David Liew drdavidliew

      1 year 4 months ago
      We know HCQ adherence is poor in both RA and SLE >50% in this BC 🇨🇦 cohort All despite being such an important medicine What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C
      RT @Janetbirdope: Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality

      Janet Pope Janetbirdope

      1 year 4 months ago
      Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality outcomes >700 pts - half had a DMARD after dx RheumNow #EULAR2023 OP0238 Targeted Rx improved esp RTX\TCZ findings V interesting results #GameChanger May change my Rx practice!
      RT @AurelieRheumo: Retro French database study shows reassuring data.

      Overall mortality after IRAEs =similar between p

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      Retro French database study shows reassuring data. Overall mortality after IRAEs =similar between pts receiving b/tsDMARDs vs. those who don't 70000+ pts treated w/ ICI, 7800+ IRAEs (most frequent colitis) & 330 treated w/ b/tsDMARDs, 10% Rheum IRAE OP0270 @RheumNow #EULAR23 https://t.co/OFNaIU4kzt
      RT @synovialjoints: Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE
      RT @bella_mehta: Fatigue in SLE remains a challenge!
      Online digital tool - LEAF - Lupus Expert System for Assessment of

      Bella Mehta bella_mehta

      1 year 4 months ago
      Fatigue in SLE remains a challenge! Online digital tool - LEAF - Lupus Expert System for Assessment of Fatigue - assement of fatigue PROMs in 1250pts - 80% reported fatigue, 93% found tool helpful @rheumnow #EULAR2023 Need more tools to assess and manage fatigue! abst#OP0230
      RT @Yuz6Yusof: #EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in R

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #POS1075 Which biologics have the lowest retention rate in Elderly patients (=>65 yrs) in Rheumatoid Arthritis? Data from Italian registry showed 1/3 discontinued biologics at 2 yrs. IL6-i: lowest persistence; Abatacept: highest @RheumNow https://t.co/28n4qzR3aM
      RT @drdavidliew: Can’t escape ORAL Surveillance RCT talk

      Lots of real world data on CV risk & JAKi here
      (with all

      David Liew drdavidliew

      1 year 4 months ago
      Can’t escape ORAL Surveillance RCT talk Lots of real world data on CV risk & JAKi here (with all the selection, measurement bias) First up: multinational JAK-pot study (n=>50k) Even if you mirror the high-risk RCT cohort - not much there for MACE OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri
      RT @Janetbirdope: No new predictors for decline in #SSc lung function in ILD Progression of #scleroderma Lung disease is

      Janet Pope Janetbirdope

      1 year 4 months ago
      No new predictors for decline in #SSc lung function in ILD Progression of #scleroderma Lung disease is common - risks male, dcSSc, low FVC, Topo1 ⁦@RheumNow⁩ #EULAR2023, OP0236 ⁦@eular_org⁩ https://t.co/bTxTyLE8dZ
      RT @AurelieRheumo: An AI algorithm to predict opined related deaths

      UK database >1000000 pts, 1200+ opioids relate

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      An AI algorithm to predict opined related deaths UK database >1000000 pts, 1200+ opioids related deaths Risk factors: Substance used disorder Hx self harm Alcohol abuse Oxycodone Liver disease Concomitant gabapentinoids & BZD *no pictures allowed* @Rheumnow OP0269 #EULAR23 https://t.co/II96fnhqy3

      Podcasts

      • ANA+ Consult (10.18.2024)
      • Dot The I, Cross The T (10.11.2024)
      • Stop Counting Bugs (10.4.2024)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.